Filed By

SEP 2 1 2020

## BEFORE THE KANSAS BOARD OF PHARMACY

In the Matter of	)		BOARD OF PHARMACY
HALLANDALE PHARMACY	)	Case No. 19-397	
Kansas Registration No. 22-102800	)		

## STIPULATION AND CONSENT ORDER

IT IS HEREBY STIPULATED AND AGREED by and between the Kansas Pharmacy Board (the "Board") and Hallandale Pharmacy located at 2666 SW 36<sup>th</sup> Street, Ft. Lauderdale, Florida 33312 ("Respondent") as follows:

1. The Board is represented herein by its attorney, Randall J. Forbes of Frieden & Forbes, LLP, 1414 SW Ashworth Place, Suite 201, Topeka, Kansas 66604. The Respondent is represented herein by its attorney, Paul P. Drake, FL Bar No. 115451, and Edwin A. Bayó, FL Bar No. 327727

- 2. The Board is the Kansas agency vested with the authority to carry out and enforce the provisions of the Kansas Pharmacy Law, K.S.A. 65-1626 *et seq.*, ("Act") including conducting hearings and proceedings to revoke, suspend or otherwise discipline a Kansas registration to operate a pharmacy.
- 3. The Respondent is presently entitled to operate a non-resident pharmacy in the State of Kansas by reason of the Board having issued it Kansas non-resident pharmacy registration number 22-102800 ("Kansas Registration"). At all times relevant hereto, the Respondent has held a current registration to operate a Kansas non-resident pharmacy at 2666 SW 36<sup>th</sup> Street, Ft. Lauderdale, Florida 33312 ("Pharmacy").

- 4. The Board's Investigation Member has received certain information, investigated and determined that there are reasonable grounds to believe that Respondent has operated in a manner that violates the Act.
- 5. Respondent hereby waives any further proof in this or any other proceeding before or initiated by the Board with respect to this matter, and upon motion duly made, seconded and passed, the Board finds the following:
- A. On March 7, 2019 Respondent was disciplined by the Alaska Pharmacy Board for shipping prescription drugs into Alaska without a valid license to do so ("Alaska Discipline").
- B. On January 28, 2019 the Minnesota Pharmacy Board denied Respondent's renewal application due to deficient inspections and on June 19, 2019 the same Board issued a cease and desist order to Respondent for continuing to ship prescription drugs into that state after the renewal application was denied (collectively the "Minnesota Discipline").
- C. On May 29, 2019, the Louisiana Pharmacy Board disciplined Respondent for shipping prescription drugs into Louisiana without a valid permit to do so ("Louisiana Discipline").
- D. On July 2, 2019, the Texas Board of Pharmacy disciplined Respondent for failure to disclose that Respondent had been disciplined in another state ("Texas Discipline").
- E. On November 20, 2019, the Colorado Board of Pharmacy disciplined Respondent for failure to disclose that Respondent had been disciplined in another state ("Colorado Discipline").
- F. On December 18, 2019, the Maryland Board of Pharmacy disciplined Respondent for failure to report a move, failure to report discipline in another state, and inspection deficiencies ("Maryland Discipline").

G. On June 10, 2019, the Kansas Board of Pharmacy entered a Stipulation and Consent

Order in Case No. 17-185 disciplining Respondent for various reasons including failure to

disclose to the Kansas Board a November 2, 2017 discipline of Respondent by the Oklahoma

Pharmacy Board ("Kansas Order"). Among other things, the Kansas Order provided that

Respondent must comply with the Act and the Board's rules and regulations.

H. K.S.A. 68-2-23 requires that the owner of any pharmacy notify the Board in writing

within 30 days of any discipline taken by any jurisdiction against the pharmacy or its license or

registration.

I. Respondent failed to notify the Board of the Alaska Discipline, Minnesota

Discipline, Louisiana Discipline, Texas Discipline, Colorado Discipline and Maryland

Discipline within 30 days as required by K.S.A. 68-2-23.

J. On June 4, 2019, the Board received Respondent's application to renew its Kansas

non-resident pharmacy registration ("Renewal Application"). Although Respondent's Renewal

Application disclosed that it had been disciplined by other jurisdictions, Respondent failed to

disclose the Alaska Discipline and the Louisiana Discipline.

K. Respondent violated the Kansas Order by failing to notify the Board of the Texas

Discipline, Colorado Discipline and Maryland Discipline within 30 days as required by K.S.A.

68-2-23.

6. Upon motion duly made, seconded and passed, the Board finds and concludes that

the events described in paragraph 5 above, constitute the operation of a pharmacy in a manner

that violates the Act and the Regulations of the Board and is therefore grounds for disciplinary

action against the Respondent's Kansas Registration pursuant to K.S.A. 65-1627 (e)(1).

- 7. The Respondent agrees and consents and the Board finds concludes and orders that the following disposition is just and appropriate under the circumstances:
- A. ADMINISTRATIVE FINE. Within ten (10) days of the Board entering the Consent Order provided for herein, Respondent shall pay to the Kansas Pharmacy Board an administrative fine in the amount of Nine Thousand Dollars (\$9,000.00).
- B. PROBATION. Respondent's non-resident pharmacy registration shall be on a probationary status for a period of three (3) years form the effective date of the Consent Order contemplated hereby.
- C. OTHER REQUIREMENTS. Respondent acknowledges and agrees that as a condition of this Stipulation and Consent Order it must, and the Board further orders the Respondent to:
  - i. Comply fully with this Stipulation and Consent Order;
  - ii. Comply fully with the Kansas Pharmacy Act, the Board's rules and regulations and all state and federal laws relating to Kansas pharmacies;
- 8. Respondent agrees that all information in the possession of the Board's Investigation Member, its staff, its investigators and or its attorney regarding the investigation which lead to this disciplinary action and all information discovered during the pendency of the disciplinary action may be disclosed to and considered by the Board as part of the presentation and consideration of the proposal of settlement in the form of this Stipulation and Consent Order and the Final Order provided for herein, with or without the presence of the Respondent or its attorney. In the event that this Stipulation and Consent Order and the Final Order provided for herein are not accepted and approved by the Board, the Respondent further waives any objection to the Board members' consideration of this Stipulation and Consent Order or the information mentioned in the preceding sentence and further agrees to waive any claim of due process

violation or the right to seek the disqualification of any Board member as a result of the Board member's consideration of said document and information.

9. The stipulations contained herein shall not become binding until this Stipulation

and Consent Order is approved by the Board and the Consent Order provided for herein is entered

by the Board. The Respondent acknowledges that the approval of the Board's Investigation

Member or its attorney shall not constitute the approval of the Board or bind the Board to approve

this Stipulation and Consent Order.

10. The Respondent agrees that this Stipulation and Consent Order is in conformance

with Kansas and federal law and the Board has jurisdiction to enter into it and enter the Final

Order provided for herein. The Respondent further agrees, for purposes of this matter, that the

Kansas Pharmacy Act, K.S.A. 65-1626 et seq. is constitutional on its face and as applied in this

case.

11. This Stipulation constitutes the entire agreement of the parties and may only be

modified by a subsequent writing signed by them. The agreement shall be interpreted in

accordance with the laws of the State of Kansas.

12. The Respondent acknowledges that it has the following rights:

(a) To have formal notice of charges served upon it;

(b) To file a response to the charges;

(c) To have notice of and participate in a formal adjudicative hearing with

the Board or its designee making specific findings of facts and conclusions of law based only

upon evidence admitted at such hearing; and

(d) To take advantage of all applicable provisions of the Kansas

Administrative Procedure Act, K.S.A. 77-501 et seq. and the Kansas Judicial Review Act, K.S.A.

77-601 et seq.

The Respondent freely waives these rights and acknowledges that said waiver is made

voluntarily and in consideration of the Board's limiting the disciplinary action taken against it to

those provided for herein. The Respondent further waives the right to seek reconsideration or

appeal or otherwise contest this Stipulation and Consent Order provided for herein.

13. The Respondent acknowledges that it enters into this Stipulation and Consent

Order freely and voluntarily after consultation with counsel of its choosing. The Respondent

further acknowledges that it has read this Stipulation and Consent Agency order in its entirety,

that it understands its legal consequences and that it agrees that none of its terms are

unconscionable, arbitrary or capricious.

14. Time is of the essence to this Stipulation and Consent Order. Respondent

acknowledges and agrees that any violation of this Stipulation and Consent Order shall constitute

a willful violation of a lawful Board order and grounds for further disciplinary action against it.

The pendency of any disciplinary action arising out of an alleged violation of this Stipulation and

Consent Order shall not affect the obligation of Respondent to comply with all terms and

conditions of this Stipulation and Consent Order.

15. This Stipulation and Consent Order constitutes the entire and final agreement of

the parties. In the event any provision of this Stipulation and Consent Order is deemed invalid

or unenforceable by a court of competent jurisdiction, it shall be severed and the remaining

provisions of this Stipulation and Consent Order shall be given full force and effect.

Matter of Hallandale Pharmacy, No. 19-397 (Kan. Bd. of Pharmacy)

16. Upon approval and entry of the Final Order by the Board, this Stipulation and Consent Order shall be a public record in the custody of the Board.

17. This Stipulation and Consent Order shall become effective on the day it is

approved, accepted and made an order of the Board by way of signature of the Board's authorized

representative.

18. The Respondent acknowledges that it has been advised by the Board that it would

have the right within 15 days after service of the Final Order provided for herein to file a petition

for reconsideration with the Board and the right within 30 days after service of the Final Order

provided for herein to file a petition for judicial review in the District Court of Shawnee County,

Kansas in accordance with the Kansas Judicial Review Act, K.S.A. 77-601 et seq. and to serve

such a petition for judicial review on the Kansas Board of Pharmacy by serving Alexandra Blasi,

JD, MBA, its Executive Secretary at 800 SW Jackson St., Suite 1414, Topeka, KS 66612. The

Respondent hereby waives those rights.

ENTERED AND EFFECTIVE this 21st day of September, 2020.

KANSAS BOARD OF PHARMACY

By:

. JONATHAN BRUNSWIG, President

## AGREED AND APPROVED BY:

Hallandale Pharmacy 2666 SW 36th Street Ft. Lauderdale, FL 33312 6/23/2020 Date

Dr. Terica Gatewood & Investigation Member

Grossman, Furlow, and Bayo Law Firm 2022-2 Raymond Diehl Rd., Tallahassee, FL 32308

Respondent's Attorney's Name & Address

6/23/2020 Date

Randall J. Forbes, KS#09089 MO#64335 FRIEDEN & FORBES, LLP

1414 SW Ashworth Place, Suite 201

Topeka, KS 66604 (785) 354-1100

## **CERTIFICATE OF SERVICE**

The undersigned hereby certifies that a copy of the foregoing STIPULATION AND CONSENT ORDER was served by depositing same in the United States mail, postage prepaid, this 21st day of September , 2020 addressed to:

Randall J. Forbes FRIEDEN & FORBES, LLP 1414 SW Ashworth Place, Suite 201 Topeka, KS 66604

Hallandale Pharmacy c/o David Robbani 2666 SW 36<sup>th</sup> Street Ft. Lauderdale, FL 33312

Representative of the

KANSAS BOARD OF PHARMACY